Japanese drugmaker Takeda’s (TYO: 4502) latest financial results were presented Thursday, though they took a back seat to the news that the group’s long-term chief executive Christophe Weber is to retire in 2026.
He has been credited with leading a major transformation in his 12-year reign at Takeda, which has announced results after the third quarter of Japan’s financial year, along with forecasts for the year as a whole.
Revenue for the first three quarters grew by nearly 10% to 3,528.2 billion yen ($22.83 billion), while operating profit for the nine-month period was 417.5 billion yen, up 86%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze